Cambridge Healthtech Institute’s Second Annual

Personalized Cancer Vaccines and Neoantigen Targeted Therapies

Personalized Cancer Immunotherapy in the Genomic Era
August 31-September 1, 2017 | Sheraton Boston | Boston, MA

Fueled with advances in genomic technologies, personalized oncology promises to innovate cancer therapy and target previously undruggable space. Developments in NGS technology enabled systematic analysis of patient-specific mutanome and open the door to developing personalized cancer vaccines targeting neoantigens. The personalized vaccines used alone or in combination with other immunotherapies are enabling the next generation of cancer therapy. Cambridge Healthtech Institute’s Second Annual Personalized Cancer Vaccines and Neoantigen Targeted Therapies meeting brings together thought leaders from pharmaceutical and biotech companies, leading academic teams and clinical immuno-oncologists to share research and case studies in implementing patient-centric approaches to using the immune system to beat cancer, including utilizing NGS to identify tumor-specific neoantigens, using in silico tools to predict immunogenic neoepitopes, and targeting them with personalized vaccines or vaccine combination therapies.

Preliminary Agenda


Genetically Engineered DC Vaccines for Melanoma

Lisa H. Butterfield, Ph.D., Professor, Medicine, Surgery and Immunology, University of Pittsburgh

Cancer Vaccines in the Era of Checkpoint Blockade

Willem W. Overwijk, Ph.D., Professor, Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center


Leveraging the Neo-Repertoire of Tumor-Specific Th1 Epitopes for Multiantigen Cancer Vaccines

William Watt, Ph.D., President & CEO, EpiThany

Neoantigen-Based Vaccines for Breast Cancer

Keith Knutson, Ph.D., Director, Cancer Vaccine & Immune Therapies Program, Mayo Clinic

Generation of Cost-Effective and Immunogenic Private Neoantigen-Based DNA Vaccines

Agnete Fredriksen, Ph.D., CSO, Vaccibody

In vivo Delivery of Multiple Conserved Tumor Antigens, Neoepitopes and Immune Response Enhancers with Dendritic Dell Targeting Lentiviral Vector ZVexMulti

Jan ter Meulen, M.D., CSO, Immune Design

Discovery of the Best Checkpoint Blockade Partner for in situ Vaccination

Joshua Brody, M.D., Director, Lymphoma Immunotherapy Program, Icahn School of Medicine at Mount Sinai


Development of Monoclonal Antibodies Targeting Functional Neoantigens in Solid Tumors

Philip M. Arlen, M.D., President & CEO, Precision Biologics

Antigen Cascade – Using Self-Antigen Directed Vaccines to Target Neoepitopes

Christopher R. Heery, M.D., CMO, Bavarian Nordic

High-Throughput Functional Screening of Neoantigens for Vaccines and TCR-Based Adoptive T Cell Therapies

Dolores J. Schendel, Ph.D., CEO & CSO, Medigene

Comprehensive Profiling of T Cell Responses to Putative Neoantigens Reveals Smarter Targets for Cancer Immunotherapy

Theresa Zhang, Ph.D., Vice President, Personalized Cancer Vaccines, Genocea Biosciences

For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences

For exhibit & sponsorship opportunities, please contact:

Rod Eymael
Manager, Business Development

YouTubeOutlookYouTubeLinkedInTwitter #IOSummit  

Japan-Flag   Korea-Flag   China-Simplified-Flag   China-Traditional-Flag

Register Today